MGRX (Mangoceuticals, Inc., NASDAQ) up 50.75% intraday 20 Feb 2026: TRT sales drive heavy volume

Mangoceuticals, Inc. (MGRX) experienced a significant 50.75% intraday surge on February 20, 2026, driven by strong initial sales results from its $99 injectable TRT program. The company reported 336% month-over-month sales growth and a 54% reduction in customer acquisition cost, leading to a massive volume spike of nearly 300 million shares. While strong TRT sales propelled the stock, Meyka AI’s model projects a 12-month fair value of USD 0.26, indicating potential downside due to ongoing net losses and liquidity risks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin